Eli Lilly is acquiring blood cancer drug developer Ajax Therapeutics for up to $2.3 billion
Source ↗
👁 0
💬 0
The deal centers on AJ1-11095, a first-in-class experimental oral drug in early-stage trials for myelofibrosis patients
Comments (0)